Abstract
Advances in combinatorial chemistry, high-throughput screening, and molecular modeling have revolutionized the process of drug discovery in the pharmaceutical industry. Drug discovery efforts for the primary protozoal parasitic diseases of the developing world, malaria, leishmaniasis, and trypanosomiasis, have also begun to employ these tech-niques. Drug targets in these parasites, exemplified by cysteine proteases and trypanothione reductase, have been purified and used for inhibitor screening. Through this work, small molecules have been identified that inhibit both parasite proteins and the growth of the organisms. This review describes advances that have been made in examining the effects of small molecules on potential parasitic drug targets determined by biochemical and computer-based screening, and also details the activity of such compounds on parasites in vitro and in vivo. Based on these results, it is apparent that modern drug discovery techniques hold promise for the identification of antiparasitic drug candidates.
Keywords: malaria, leishmaniasis, combinatorial chemistry, high throughput screening, molecular modeling, parasitic diseases, rhodesiense, plasmodium, anopheles, leishmania, trypanosoma brucei, trypansoma cruzi, antileishmanial, antitrypanosomal, trypanothione reductase, polyamine derivatives, proteases, cruzain, serine oligopeptidase, trypanopain Tb, transporters, trypanosome transporters, nucleic acid synthesis, leishmania nucleoside transporters, cruzi diamine transporter, hexose transporter, glycolytic enzyme, phosphoribosyltransferases, tubulin, malarial proteases, falcipain inhibitors, plasmepsin inhibitors, lactate dehydrogenase
Current Medicinal Chemistry
Title: Target-Based Drug Discovery for Malaria, Leishmaniasis, and Trypanosomiasis
Volume: 7 Issue: 8
Author(s): Karl A. Werbovetz
Affiliation:
Keywords: malaria, leishmaniasis, combinatorial chemistry, high throughput screening, molecular modeling, parasitic diseases, rhodesiense, plasmodium, anopheles, leishmania, trypanosoma brucei, trypansoma cruzi, antileishmanial, antitrypanosomal, trypanothione reductase, polyamine derivatives, proteases, cruzain, serine oligopeptidase, trypanopain Tb, transporters, trypanosome transporters, nucleic acid synthesis, leishmania nucleoside transporters, cruzi diamine transporter, hexose transporter, glycolytic enzyme, phosphoribosyltransferases, tubulin, malarial proteases, falcipain inhibitors, plasmepsin inhibitors, lactate dehydrogenase
Abstract: Advances in combinatorial chemistry, high-throughput screening, and molecular modeling have revolutionized the process of drug discovery in the pharmaceutical industry. Drug discovery efforts for the primary protozoal parasitic diseases of the developing world, malaria, leishmaniasis, and trypanosomiasis, have also begun to employ these tech-niques. Drug targets in these parasites, exemplified by cysteine proteases and trypanothione reductase, have been purified and used for inhibitor screening. Through this work, small molecules have been identified that inhibit both parasite proteins and the growth of the organisms. This review describes advances that have been made in examining the effects of small molecules on potential parasitic drug targets determined by biochemical and computer-based screening, and also details the activity of such compounds on parasites in vitro and in vivo. Based on these results, it is apparent that modern drug discovery techniques hold promise for the identification of antiparasitic drug candidates.
Export Options
About this article
Cite this article as:
Werbovetz A. Karl, Target-Based Drug Discovery for Malaria, Leishmaniasis, and Trypanosomiasis, Current Medicinal Chemistry 2000; 7 (8) . https://dx.doi.org/10.2174/0929867003374615
DOI https://dx.doi.org/10.2174/0929867003374615 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements